Amgen announces denosumab results webcast

A webcast of a conference call will be made available on the internet for parties interested in its denosumab phase III head-to-head versus alendronate study results, Amgen says.

Taking place today, the conference call will include input from principal study investigator, Jacques P Brown, head of the division of rheumatology at Le Centre hospitalier universitaire de Quebec.

Also present will be Catherine Stehman-Breen, Amgen’s vice-president of global development, bone therapeutics.

Live audio of the conference call, which will last about an hour including a questions and answers session, will be relayed over the internet and available to members of the news media, investors and the general public.

The webcast will be available for replay via the company website for up to 72 hours after the event, the company stated.

According to Amgen, denosumab is the “first fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand, an essential regulator of osteoclasts”.